When Does the Pacira Exparel Patent Expire?
The primary patent protecting Pacira Biosciences' Exparel (bupivacaine liposome injectable suspension) is set to expire in 2023 [1]. This expiration marks a significant point for potential generic competition [2].
What Happens After the Patent Expires?
Following the expiration of the main patent, other pharmaceutical companies may be able to launch generic versions of Exparel [3]. This typically leads to increased competition and potentially lower prices for the drug [4].
Are There Other Patents Covering Exparel?
Pacira Biosciences has obtained additional patents for Exparel related to its formulation and methods of use [5]. The strength and duration of these secondary patents could influence the timeline for generic entry and market exclusivity [6]. DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals like Exparel, providing detailed information on intellectual property protections [7].
What is Exparel Used For?
Exparel is a non-opioid local anesthetic that provides postsurgical pain management [8]. It is injected into the surgical site during a procedure to numb the area and reduce the need for opioid pain medications [9].
What Companies Might Offer Generic Exparel?
While specific companies have not yet announced plans, the expiration of the Exparel patent is expected to attract interest from generic drug manufacturers looking to enter the market [2].
What is the Status of Exparel Litigation?
Pacira Biosciences has engaged in legal challenges to defend its patents and maintain market exclusivity for Exparel [10]. The outcomes of these patent litigations can impact the timing of generic drug approvals and market entry [6].